earningsconfidence high
NeuroPace Q1 RNS rev $21.7M (+19.5%); raises FY26 rev guidance to $99-101M
NeuroPace Inc
2026-Q1 EPS
reported -$0.20
vs consensus -$0.23
▲ beat
(+14.7%)
- RNS System revenue $21.7M (+19.5% YoY); total revenue $22.1M including $0.1M DIXI Medical.
- GAAP net loss $6.7M; Adjusted EBITDA loss ex DIXI improved to $3.3M from $4.1M YoY.
- Cash $54.8M vs $61.2M prior quarter; long-term debt $59M.
- FY2026 revenue guidance raised to $99-101M (from $98-100M), representing 21-23% RNS growth.
- Expects IGE indication expansion contribution after potential NAUTILUS PMA-S approval mid-2026.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.